Pancreatic cancer
Conditions
Interventions
A total of three courses of nab-Paclitaxel and Gemcitabine followed by TS-1 with concurrent radiotherapy of 45Gy for 5 weeks
Sponsors
Keio University School of Medicine
Department of Surgery, Tochigi Medical Center Department of Surgery, Ichikawa General Hospital, Tokyo Dental College Department of Surgery, Tokyo Medical Center Department of Surgery, Saitama National Hospital Department of Surgery, Hiratsuka City Hospital Department of Surgery, Fussa Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically proven or radiologically confirmed pancreatic cancer 2) No prior treatment for pancreatic cancer 3) Age between 20 to 85 4) ECOG performance status 0/1 5) White blood cell count above 3000/mm3 Neutrophil count above 1000/mm3 Platelet count above 100000/mm3 Hemoglobin above 8.0 g/dl Total billirubin below 3.0 mg/dl AST, ALT below 150 IU/L Creatinine below 1.5 mg/dl 6) No exclusion criteria 7) Proper informed consent
Exclusion criteria
Exclusion criteria: 1) Contraindication of nab-PTX, GEM, TS-1 2) Pleuritic effusion refractory to diuretics 3) Presence of distant metastasis 4) Presence of concurrent advanced cancer 5) Presence of clinically obvious infection 6) Prior radiotherapy to abdominal lesions 7) Previous history of myocardial infarction within three months 8) Severely mental retardation 9) Current status of pregnancy and lactation, or the possibility of these statuses.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resection rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse-free survival Overall survival Treatment completion rate Adverse effect Pathological response | — |
Countries
Japan
Contacts
Public ContactMinoru Kitago
Keio University School of Medicine Department of Surgery
Outcome results
None listed